Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III NSCLC

NCT06448910 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

41

Enrollment

OTHER

Sponsor class

Conditions

NSCLC
Locally Advanced Lung Carcinoma

Interventions

DRUG: Cadonilimab (AK104)

Sponsor

Fudan University